Results 71 to 80 of about 31,974 (99)

G. Schwartz, Die Besetzung der Bistümer Reichsitaliens unter den Sächsischen und Salischen Kaisern mit den Listen der Bischöfe 951–1122 H. Pahncke, Geschichte der Bischöfe Italiens deutscher Nation von 951–1264

, 1914
Ernst Pereis
semanticscholar   +1 more source

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

The Oncologist, 2013
B. Wolpin, K. Ng, A. Zhu, T. Abrams, P. Enzinger, N. McCleary, D. Schrag, E. Kwak, Jill N. Allen, P. Bhargava, J. Chan, W. Goessling, L. Blaszkowsky, J. Supko, M. Elliot, Kaori Sato, E. Regan, J. Meyerhardt, C. Fuchs   +18 more
semanticscholar   +1 more source

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.

European Journal of Cancer, 2013
M. Fishman, Sandy Srinivas, R. Hauke, R. J. Amato, B. Esteves, M. Cotreau, A. Strahs, W. Slichenmyer, P. Bhargava, F. Kabbinavar   +9 more
semanticscholar   +1 more source

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Clinical Cancer Research, 2011
F. Eskens, M. D. de Jonge, P. Bhargava, T. Isoe, M. Cotreau, B. Esteves, K. Hayashi, H. Burger, M. Thomeer, L. van Doorn, J. Verweij   +10 more
semanticscholar   +1 more source

Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration.

American Journal of Clinical Pathology, 2009
G. Carulli, A. Stacchini, A. Marini, M. M. Ciriello, A. Zucca, E. Cannizzo, S. Aliberti, A. Demurtas, D. Novero, L. Calcagno, T. Callegari, M. Petrini   +11 more
semanticscholar   +1 more source

Publisher Correction: Pre-conceptional paternal diet impacts on offspring testosterone homoeostasis via epigenetic modulation of cyp19a1/aromatase activity

npj Metabolic Health and Disease
Arianna Pastore, Nadia Badolati, Francesco Manfrevola, Serena Sagliocchi, Valentina Laurenzi, Giorgia Musto, Veronica Porreca, Melania Murolo, Teresa Chioccarelli, Roberto Ciampaglia, Valentina Vellecco, Mariarosaria Bucci, Monica Dentice, Gilda Cobellis, Mariano Stornaiuolo   +14 more
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: comparative study against recombinant erythropoietin in rat.

European Journal of Pharmacology, 2021
Anemia with inflammation-induced defective iron utilization is a pathological condition observed in patients suffering from chronic kidney disease (CKD) or chronic inflammatory disease.
Y. Shinozaki, K. Fukui, Hatsue Kobayashi, H. Yoshiuchi, A. Matsuo, M. Matsushita   +5 more
semanticscholar   +1 more source

A 951-fsrms Period Jitter 3.2% Modulation Range in-Band Modulation Spread-Spectrum Clock Generator

IEEE Journal of Solid-State Circuits, 2020
A spread-spectrum clock generator is proposed based on an in-band phase modulation. In a charge-pump phase-locked loop configuration, the input phase modulation signal is applied to the proposed charge-based discrete-time loop filter.
Hyuk Sun, Kazuki Sobue, K. Hamashita, Tejasvi Anand, U. Moon   +4 more
semanticscholar   +1 more source

JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.

European Journal of Pharmacology, 2019
JTZ-951 (enarodustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor. JTZ-951 has inhibitory activities on human HIF-prolyl hydroxylase 1-3, but not on various receptors or enzymes. In Hep3B cells, JTZ-951 increased HIF-1α and HIF-
K. Fukui, Y. Shinozaki, Hatsue Kobayashi, Katsuya Deai, H. Yoshiuchi, T. Matsui, A. Matsuo, M. Matsushita, Tetsuhiro Tanaka, M. Nangaku   +9 more
semanticscholar   +1 more source

JTZ-951, a HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.

AJP - Renal Physiology, 2019
Some preceding studies have provided evidence that hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PH inhibitors) have therapeutic potential against tubular interstitial fibrosis (TIF).
Takeshi Wakashima, Tetsuhiro Tanaka, K. Fukui, Y. Komoda, Y. Shinozaki, Hatsue Kobayashi, A. Matsuo, M. Nangaku   +7 more
semanticscholar   +1 more source